Mounjaro®
Starting from £179.99/mo
Start journey Learn moreClinical trials show that adults taking semaglutide 2.4mg (Wegovy) lost around 15% of their body weight on average over 68 weeks, alongside a reduced-calorie diet and increased activity. At the newer 7.2mg dose, that figure rises to around 20.7% over 72 weeks. Individual results vary, and how much weight you lose on Wegovy depends on your starting weight, lifestyle changes, and how your body responds — a prescriber assesses suitability before any treatment begins. Wegovy is a prescription-only medicine, so the only legal route to it in the UK is through a clinical consultation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The headline figure most people encounter is 15%. That comes from the STEP 1 trial, published in the New England Journal of Medicine, in which adults with obesity taking semaglutide 2.4mg lost roughly 15% of their body weight over 68 weeks. To put that in everyday terms: someone starting at 100kg might expect to lose around 15kg on average under trial conditions, which included structured lifestyle support.
The numbers shift at higher doses. The MHRA approved a 7.2mg maintenance dose for Wegovy in early 2026, and trial data reported average weight loss of around 20.7% over 72 weeks, approaching the results seen with tirzepatide at its highest dose. For context on how those two medicines compare at their respective ceilings, our Wegovy overview walks through the evidence side by side.
What those averages can't tell you is what your own result will be. Some participants in STEP 1 lost considerably more than 15%; others lost less. Starting BMI, adherence to lifestyle changes, how long you stay on treatment, and how your body tolerates the titration schedule all play a role. How much weight you lose on Wegovy in the real world is a conversation best had with a prescriber who can look at your individual picture.
Yes, meaningfully. Wegovy starts at 0.25mg and is titrated upward roughly every four weeks until the maintenance dose is reached, 2.4mg under the standard schedule, or 7.2mg under the newer higher-dose option. The earlier, lower doses are a settling-in period for your system; the weight-loss effect builds as the dose increases.
If you're curious about what the data shows at specific points on that ladder, we've looked at the evidence for weight loss on 1mg Wegovy, on the 1.7mg dose, and at the full 2.4mg maintenance dose in separate guides. The short version: results ramp up with the dose, and most of the meaningful loss in trials occurred once participants reached maintenance.
Some people also ask about weekly progress rather than the overall figure. The pace of loss isn't linear, early weeks tend to show faster movement, which then settles. Our page on how much you can lose each week on Wegovy covers what the trial data shows week by week, and what to expect as your body adjusts.
UK private pricing for Wegovy varies by dose and provider. Since Eli Lilly's list-price increase in September 2025 reset market expectations for GLP-1 treatments more broadly, private monthly costs for semaglutide have typically ranged roughly £149–£375 depending on the dose and what the provider includes. Those headline figures, as widely reported, don't always reflect the full picture.
A number of providers quote a per-pen price that excludes a consultation fee, a prescription charge, or aftercare, costs that can add up quietly. Some charge separately for dose reviews, or require a subscription you'd need to cancel. Our Wegovy pricing guide breaks down what to look for before you commit to any provider.
At nume, one price covers the consultation, prescription, the medicine, free next-working-day delivery, and seven-day aftercare support. We don't run discount codes or promotional offers, and we're upfront that we're not the cheapest option available. What that price buys is a regulated supply chain, a named prescriber reviewing your case rather than software, and support if questions arise after your order arrives. Current treatment pricing is shown on our treatment page, updated as doses change.
For most purchases, price is a sensible filter. For a prescription medicine sourced online, it's the wrong one to lead with. The MHRA has issued repeated warnings about counterfeit semaglutide pens sold through social media and unofficial channels, fake products that have, in some cases, contained insulin rather than semaglutide. Reporting to the MHRA via the Yellow Card scheme is the correct route if you encounter a suspect seller.
Any legitimate UK source for Wegovy requires a prescription following clinical assessment. A seller offering these medicines without one is operating outside the law, whatever the price. You can verify that any online pharmacy is GPhC-registered at the pharmacy register, our premises number is 9012878. The medicines arriving from a verified, regulated pharmacy in the licensed UK supply chain is the measure that actually matters. The saving from the cheapest listing answers a different question than the one that keeps you safe.
If you'd like to understand whether Wegovy is clinically suitable for you (including the eligibility criteria around BMI and any weight-related conditions) our page on how much you have to weigh to get Wegovy covers that in detail.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.